Skip to main content

Advertisement

SpringerLink
Log in

Collagen gel droplet-embedded culture drug sensitivity test (CD-DST) predicts the effect of adjuvant chemotherapy on pancreatic cancer

  • Original Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Purpose

We evaluated the clinical effectiveness of collagen gel droplet-embedded culture drug sensitivity tests (CD-DSTs) in predicting the efficacy of adjuvant chemo-therapeutic treatments for pancreatic cancer (PC).

Methods

The clinicopathological characteristics and prognoses of 22 PC patients who underwent CD-DST after pancreatectomy at Tohoku University between 2012 and 2016 were analyzed retrospectively. Eligibility criteria were resectable or borderline resectable PC, successful evaluation for 5-fluorouracil sensitivity by CD-DST, treatment with S-1 adjuvant chemotherapy, and no preoperative chemotherapy.

Results

The rate of successful evaluation by CD-DST was 52.3% in PC. The optimal T/C ratio, defined as the ratio of the number of cancer cells in the treatment group (T) to that in the control group (C), for 5-fluorouracil was 85% using receiver operating characteristic curve analysis. The sensitive group (T/C ratio < 85%; n = 11) had a better recurrence-free survival rate than the resistant group (T/C ratio ≥ 85%; n = 11; P = 0.029). A Cox proportional hazards regression model demonstrated that sensitivity to 5-fluorouracil was an independent predictor of recurrence on multivariate analysis (hazard ratio 3.28; 95.0% CI 1.20–9.84; P = 0.020).

Conclusions

CD-DSTs helped to predict PC recurrence after S-1 adjuvant chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH, et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2018;267:936–45.

    Article  Google Scholar 

  2. National Comprehensive Cancer Network. NCCN guidelines version.018 pancreatic adenocarcinoma. https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.

  3. Michalski CW, Erkan M, Sauliunaite D, Giese T, Stratmann R, Sartori C, et al. Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. Br J Cancer. 2008;99:760–7.

    Article  CAS  Google Scholar 

  4. Tanigawa N, Yamaue H, Ohyama S, Sakuramoto S, Inada T, Kodera Y, et al. Exploratory phase ii trial in a multicenter setting to evaluate the clinical value of a chemosensitivity test in patients with gastric cancer (JACCRO-GC 04, Kubota memorial trial). Gastric Cancer. 2016;19:350–60.

    Article  CAS  Google Scholar 

  5. Mekata E, Sonoda H, Shimizu T, Tatsuta T, Yamaguchi T, Endo Y, et al. Clinical predictive value of in vitro anticancer drug sensitivity test for the therapeutic effect of adjuvant chemotherapy in patients with stages II–III colorectal cancer. Mol Clin Oncol. 2013;1:763–7.

    Article  CAS  Google Scholar 

  6. Kobayashi H, Tanisaka K, Doi O, Kodama K, Higashiyama M, Nakagawa H, et al. An in vitro chemosensitivity test for solid human tumors using collagen gel droplet embedded cultures. Int J Oncol. 1997;11:449–55.

    CAS  PubMed  Google Scholar 

  7. Yasuda H, Takada T, Wada K, Amano H, Isaka T, Yoshida M, et al. A new in-vitro drug sensitivity test (collagen-gel droplet embedded-culture drug sensitivity test) in carcinomas of pancreas and biliary tract: possible clinical utility. J Hepatobiliary Pancreat Surg. 1998;5:261–8.

    Article  CAS  Google Scholar 

  8. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501:346–54.

    CAS  Google Scholar 

  9. Maejima K, Tokunaga A, Kiyama T, Kanno H, Bou H, Watanabe M, et al. Chemosensitivity test for 5-fluorouracil and 5-chloro-2,4-dihydroxypyridine predicts outcome of gastric cancer patients receiving s-1 postoperatively. Gastric Cancer. 2010;13:231–7.

    Article  CAS  Google Scholar 

  10. Naitoh H, Yamamoto H, Murata S, Kobayashi H, Inoue K, Tani T. Stratified phase II trial to establish the usefulness of the collagen gel droplet embedded culture-drug sensitivity test (CD-DST) for advanced gastric cancer. Gastric Cancer. 2014;17:630–7.

    Article  CAS  Google Scholar 

  11. Higashiyama M, Oda K, Okami J, Maeda J, Kodama K, Imamura F, et al. Prediction of chemotherapeutic effect on postoperative recurrence by in vitro anticancer drug sensitivity testing in non-small cell lung cancer patients. Lung Cancer. 2010;68:472–7.

    Article  Google Scholar 

  12. Kawamura M, Gika M, Abiko T, Inoue Y, Oyama T, Izumi Y, et al. Clinical evaluation of chemosensitivity testing for patients with unresectable non-small cell lung cancer (NSCLC) using collagen gel droplet embedded culture drug sensitivity test (CD-DST). Cancer Chemother Pharmacol. 2007;59:507–13.

    Article  CAS  Google Scholar 

  13. Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Nagayasu K, et al. Impact of the individualization of the first-line chemotherapy for advanced colorectal cancer based on collagen gel droplet-embedded drug sensitivity test. Oncol Lett. 2017;14:6045–52.

    PubMed  PubMed Central  Google Scholar 

  14. Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of s-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–57.

    Article  CAS  Google Scholar 

  15. Japan Pancreas Society. Classification of pancreatic carcinoma, 4th English ed. Tokyo: Kanehara & Co., Ltd.; 2017.

    Google Scholar 

  16. Motoi F, Satoi S, Honda G, Wada K, Shinchi H, Matsumoto I, et al. A single-arm, phase ii trial of neoadjuvant gemcitabine and s1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: Prep-01 study. J Gastroenterol. 2019;54:194–203.

    Article  CAS  Google Scholar 

  17. Satoi S, Yamaue H, Kato K, Takahashi S, Hirono S, Takeda S, et al. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2013;20:590–600.

    Article  Google Scholar 

  18. Ariake K, Motoi F, Mizuma M, Murakami K, Takadate T, Ohtsuka H, et al. Locally advanced pancreatic cancer successfully treated by distal pancreatectomy with celiac axis resection (DP-CAR) after s-1 with radiation therapy followed by gemcitabine/nab-paclitaxel therapy: a case report. Surg Case Rep. 2017;3:15.

    Article  Google Scholar 

  19. Bai J, Sata N, Nagai H. Gene expression analysis for predicting gemcitabine sensitivity in pancreatic cancer patients. HPB (Oxford). 2007;9:150–5.

    Article  Google Scholar 

Download references

Funding

This work was supported in part by a Grant-in-Aid for Scientific Research (24592018) from the Japan Society for the Promotion of Science.

Author information

Authors and Affiliations

  1. Department of Surgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan

    Kyohei Ariake, Fuyuhiko Motoi, Masamichi Mizuma, Hideo Ohtsuka, Hiroki Hayashi, Kei Nakagawa, Tatsuo Hata, Katsutaka Mitachi, Takeshi Naitoh, Takashi Kamei & Michiaki Unno

Authors
  1. Kyohei Ariake
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fuyuhiko Motoi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masamichi Mizuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hideo Ohtsuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroki Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kei Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tatsuo Hata
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Katsutaka Mitachi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Takeshi Naitoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takashi Kamei
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Michiaki Unno
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fuyuhiko Motoi.

Ethics declarations

Conflict of interest

We have no conflicts of interest to disclose and we did not receive any financial support in relation to this study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 18 kb)

Supplementary file2 (DOCX 16 kb)

Supplementary file3 (DOCX 18 kb)

595_2019_1842_MOESM4_ESM.jpg

Receiver operating characteristic curve of the T/C ratios for predicting recurrence. At the intersection closest to the upper left corner (T/C ratio = 85%), the sensitivity and specificity were 61.1% and 100%, respectively. AUC, area under the curve (JPEG 200 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ariake, K., Motoi, F., Mizuma, M. et al. Collagen gel droplet-embedded culture drug sensitivity test (CD-DST) predicts the effect of adjuvant chemotherapy on pancreatic cancer. Surg Today 49, 1035–1043 (2019). https://doi.org/10.1007/s00595-019-01842-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-019-01842-5

Keywords

Search

Navigation